North America:

  • Tesla faces declining sales in Spain, Portugal, Denmark, and Sweden, while Model Y deliveries surge in Norway amidst strategic challenges.
  • Sanofi acquires Blueprint Medicines for $9.1 billion to enhance its immunology portfolio.
  • Circle Internet raises $896 million in an upsized US IPO.
  • Regeneron Pharmaceuticals reports its experimental weight-loss drug preserves muscle mass, expanding its obesity portfolio.
  • Apple appeals an EU order to enhance compatibility and share information with competitors.
  • JPMorgan CEO warns US national debt might destabilize the bond market.
  • Microsoft invests $400 million in Switzerland to enhance AI and cloud computing infrastructure.
  • James Hardie secures $3.5 billion in senior credit facilities for AZEK acquisition.
  • Voyager Technologies plans NYSE listing with a $1.6 billion valuation.

Europe:

  • GSK acquires remaining royalty interests in Trelegy Ellipta for $225 million and has linerixibat accepted for FDA review.
  • Dior appoints Jonathan Anderson as creative director for women's and men's collections.
  • Gerresheimer lowers annual targets and 2025 guidance due to weak demand, leading to a 21% stock price drop.
  • AstraZeneca reports positive outcomes in treating early-stage gastric cancer and promising results with camizestrant for breast cancer.
  • Rio Tinto signs a co-management agreement with the PKKP indigenous group after cave destruction.

Rest of the world:

  • Emirates President discusses air travel demand and supply chain issues amid tariff uncertainties.
  • Vietnam Airlines set to finalize an order for 50 Boeing 737 MAX jets.
  • Venezuela raises taxes on the private sector to offset reduced oil income.
  • SOCAR to sign new oil and gas exploration agreements in Azerbaijan with Exxon Mobil and BP.